Batoclimab eases disease severity; Immunovant backs IMVT-1402
Investigational therapy batoclimab eased disease severity for adults with generalized myasthenia gravis (gMG) in a Phase 3 trial,…
Articles by Lindsey Shapiro, PhD
MDA 2025: Digital monitoring tool for myasthenia gravis found feasible
A digital tool developed by BioSensics for remotely monitoring myasthenia gravis (MG) symptoms was found to be feasible…
MDA 2025: Responses to Zilbrysq now at over 2 years in RAISE-XT
More than two years of treatment with Zilbrysq (zilucoplan) continues to be associated with sustained clinical responses in adults…
Soliris OK’d for children with generalized myasthenia gravis
The U.S. Food and Drug Administration (FDA) has approved the expanded use of Soliris (eculizumab) for treating children with…
Focus of NORD study: Rare disease community’s lived experiences
The National Organization for Rare Disorders (NORD) is seeking participants for its survey-based study Living Rare, which aims to…
FDA agrees on design of Phase 3 trial to test Descartes-08 in MG
Cartesian Therapeutics has aligned with the U.S. Food and Drug Administration (FDA) on the design of the planned Phase…
Durable reductions in MG severity seen with Descartes-08 cell therapy
The investigational cell therapy Descartes-08 led to durable reductions in disease severity for people with myasthenia gravis (MG),…
HNSA-5487 shows antibody-lowering abilities in clinical trial
HNSA-5487, an investigational therapy being developed for potential use in myasthenia gravis (MG) and other autoimmune diseases, was safe…
Potential antibody therapy ARGX-119 may aid MuSK-MG patients
ARGX-119, an antibody designed to increase the activity of the muscle-specific kinase (MuSK) protein, protected against the development of neuromuscular…
Nipocalimab up for approval for gMG in the US
Johnson & Johnson has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of…